Imugene’s PD1-Vaxx Lung Cancer Trial Ends Early: What Investors Should Know

Imugene Ltd (IUGNF) announced an update on their ongoing clinical study.

The IMU-201 (PD1-Vaxx) IMPrinter trial, officially titled “An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1/1b Study of IMU-201, a B-Cell Immunotherapy as Monotherapy or in Combination With Atezolizumab With or Without Chemotherapy, in Adults With Non-Small Cell Lung Cancer,” was designed to test a novel cancer vaccine approach for advanced lung cancer. The study aimed to find a safe dose, see how well patients tolerate it, and look for early signs that the treatment could help slow or shrink tumors.

The main treatment is IMU-201, also called PD1-Vaxx, a cancer immunotherapy that works like a vaccine to train the immune system to target the PD-1 pathway. It was tested alone and in combination with atezolizumab, a widely used checkpoint blocker sold as Tecentriq, and standard chemotherapy to see if it could boost responses in patients who had progressed on earlier drugs or were new to immune therapy.

This was an interventional Phase 1 trial with a non-randomized, step-by-step dose escalation design across several patient groups. All patients and doctors knew which treatment they were receiving, and the main goal was treatment, not comparison between arms, with a focus on safety, dose finding, and early activity signals rather than clear survival outcomes.

The study began after initial submission in May 2020, marking Imugene’s move to test PD1-Vaxx in real-world patients with advanced non-small cell lung cancer. The trial has since been listed as terminated, and the last update to the record on March 22, 2026, signals that key safety, dosing, and feasibility data have been collected and are now informing Imugene’s next development steps.

For investors, termination of an early-stage study is a caution flag that can pressure Imugene Ltd. (IUGNF) in the short term, especially if markets view it as a setback to the PD1-Vaxx program. At the same time, early safety and dosing insights, plus any positive activity signals, may still support the value of Imugene’s broader pipeline in a lung cancer field dominated by players like Merck’s Keytruda and Roche’s Tecentriq, where new combination strategies remain in demand.

The IMU-201 PD1-Vaxx lung cancer study has been updated and is no longer enrolling, and investors can find further details and status notes on the ClinicalTrials.gov portal.

To learn more about IUGNF’s potential, visit the Imugene Ltd drug pipeline page.